Effects of high dose medroxyprogesterone acetate on endogenous granulocyte macrophage-colony stimulating factor secretion and bone marrow cellularity in patients under cytotoxic chemotherapy

Journal of Chemotherapy

Volumn 10, Issue 5, 1998, Pages 394-398

  Aydin, F ^a   Demirkazik, A ^b   Icli F ^b   Akbulut, H ^b   Samur, M ^b  

^a KARADENIZ TECHNICAL UNIVERSITY   (Turkey)

^b ANKARA UNIVERSITY   (Turkey)

Author keywords

Chemotherapy; Granulocyte macrophage colony stimulating factor; Medroxyprogesterone acetate; Neutropenia

Indexed keywords

GRANULOCYTE MACROPHAGE COLONY STIMULATING FACTOR; MEDROXYPROGESTERONE ACETATE;

ADULT; AGED; ARTICLE; BREAST CANCER; CANCER CHEMOTHERAPY; CANCER PATIENT; CLINICAL ARTICLE; CYTOTOXICITY; FEMALE; HODGKIN DISEASE; HUMAN; LUNG CANCER; MALE; NEUTROPENIA; STOMACH CANCER;

EID: 0031770804     PISSN: 1120009X     EISSN: None     Source Type: Journal    
DOI: 10.1179/joc.1998.10.5.394     Document Type: Article

References (25)

1. Jieschke JG, Burgess WA. Granulocyte colony stimulating factor and granulocyte-macrophage colony stimulating factor. N Engl J Med 1992; 327: 28-35.
2. Groopman JE, Molina JM, Scadden DT. Hematopoietic growth factors: Biology and clinical applications. N Engl J Med 1989; 321: 1449-1459.
3. Bonsignori M, Rossi G, Sturba F, et al. Protective effect of high-dose medroxyprogesterone acetate (HD-MPA) on hematological toxicity induced by chemotherapy for advanced solid tumors: A multicentric controlled clinical trial. Chemioterapia 1986; 5 (2): 134-139.
4. Wils JA. Myeloprotective effect of high-dose medroxyprogesterone acetate (MPA). Chemioterapia 1988; 7: 60-62.
5. Quesade AR, Jimeno JM, Marquez G, Aracil M. Cell cycle arrest of human hematopoietic progenitors induced by medroxyprogesterone acetate. Exp Hematol 1993; 21: 1413-1418.
6. Focan C, Baudox A, Beauduin M, et al. Improvement of hematological and general tolerance to CMF by high-dose medroxyprogesterone acetate. Adjuvant treatment for primary node positive breast cancer (Analysis of 100 patients). Anticancer Res 1986; 6: 1095-1100.
7. Gunderson S, Kvinsland S, Klepp O, et al. Chemotherapy with or without high-dose medroxyprogesterone acetate in estrogen receptor-negative advanced breast cancer. Eur J Cancer 1992; 28: 390-394.
8. Hupperests P, Wills J, Volovics L, et al. Adjuvant chemo-hormonal therapy with cyclophosphomide, doxorubicin and 5-fluorouracil (CAF) with or without medroxyprogesterone acetate for node-positive cancer patients. Update at 7-year follow-up. Ann Oncol 1995; 6: 90-91.
9. Tominaga T, Abe O, Ohshima A et al. Comparison of chemotherapy with or without medroxyprogesterone acetate for advanced or recurrent breast cancer. Eur J Cancer 1994; 30A: 959-964.
10. Amadori D, Frassinetti GL, Flamini E et al. Clinical and laboratory evaluated of the myeloprotective effect of medroxyprogesterone acetate in head and neck cancer. Eur J Cancer 1992; 28A: 1331-1334.
11. Wils JA, Bron H, Lange LV et al. A randomized comparative trial of combined versus alternating therapy with cytostatic drugs and high-dose medroxyprogesterone acetate in advanced breast cancer. Cancer 1985; 56: 1325-1331.
12. Umbach GE, Spitzer G, Drewinko B, Gercovich G, Hortobagyi G. Medroxyprogesterone acetate does not protect human bone marrow progenitor cells exposed to adriamycin in vitro. Breast Cancer Res Treat 1985; 5: 87-89.
13. Pedrazzoli P, Bacciocchi G, Da Prada GA., et al. Evaluation of the effect of medroxyprogesterone acetate on bone marrow progenitor cells. Tumori 1991; 77: 399-402.
14. Pedrazzoli P. Myeloprotective effect of medroxyprogesterone acetate (MPA). Eur J Cancer 1993; 29A, 7: 1073-1074.
15. Flamini EB, Frassinetti G, Riccobon A et al. Myeloprotective effect of high-dose medroxyprogesterone acetate on staminal cells of the granulocyte macrophage line during chemotherapy. Adv Clin Oncol 1989; 1: 407-415.
16. Kleeberg UR, Schneider PO, Kern P. Myeloprotective effect of medroxyprogesterone acetate on committed granulopoietic stem cells under cytotoxic chemotherapy. J Cancer Res Clin Oncol 1986; 111(Suppl): 110-115.
17. Nemunaitis J. Growth factors of the future. Leuk Lymphoma 1993; 9: 329-336.
18. Cebon JS, Lieschke GJ. Granulocyte-macrophage colony-stimulating factor for cancer treatment. Oncology 1994; 51: 177-188.
19. Metcalf D, Morstyn G. Colony stimulating factors: general biology. In: De Vita VT Jr, Hellman S, Rosenberg SA, eds., Biologic Therapy of Cancer, Philadelphia: J.B. Lippincott 1991: 417-444.
20. Rappoport AP, Abboud CN, Di Persio JF. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte colony stimulating factor (G-CSF): receptor biology, signal transduction and neutrophil activation. Blood Rev 1992; 6: 43-57.
21. Harmenberg J, Höglund M, Hellström-Linberg E. G-and GM-CSF in oncology and oncological haematology. Eur J Haematol 1994; 52: 1-28.
22. Omori F, Okamura S, Shimoda K, et al. Levels of human serum granulocyte colony- stimulating factor and granulocyte-macrophage colony-stimulating factor under pathological conditions. Biotherapy 1992; 4: 147-153.
23. Sallerfors B, Olofsson T. Granulocyte-macrophage colony-stimulating factor (GM-CSF) and granulocyte-colony-stimulating factor (G-CSF) in serum during induction treatment of acute leukaemia. Br J Haematol 1991; 78: 343-351.
24. Gercovich GF, Morgenfeld E, Dragosky M, et al. The effects of high parenteral doses of medroxyprogesterone acetate on myelopoiesis in patients with malignant disease. In Proc Intern Symp on Medroxyprogesterone Acetate: Geneva: 1982 Feb 24-26; 139-157.
25. th European Conference on Clinical Oncology; London: 1989, Sept 3-7, CD 3381.